Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial [Phase 1, Phase 2]
An update on the SCOPE trial evaluating selinexor, pomalidomide, and dexamethasone with or without carfilzomib in relapsed/refractory multip…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating GC012F in relapsed/refractory multiple myeloma is currently recruiting, sponsored by Gracell Biotechno…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes an early-phase study of IBI3003 for relapsed or refractory multiple myeloma that is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment [Phase 1]
This document updates a Phase 1 clinical trial evaluating belantamab mafodotin in combination with nirogacestat and pomalidomide for relapse…
-
EMA approval · 2026-02-24EMA Authorised: Lenalidomide Accord (lenalidomide) — Accord Healthcare S.L.U.
EMA has authorised Lenalidomide Accord for the treatment of multiple myeloma. The product is marketed by Accord Healthcare S.L.U.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. [EARLY_Phase 1]
An early-phase 1 clinical trial to assess the safety and preliminary efficacy of QI-019A in relapsed/refractory multiple myeloma; the study …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) [Phase 2]
This is a Phase 2 clinical trial update (REVIVE) evaluating teclistamab in combination with daratumumab for high-risk smoldering/wholedown m…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma [Phase 2]
The Phase 2 MagnetisMM-4 umbrella study evaluating elranatamab in combination with anti-cancer therapies for multiple myeloma was terminated…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating adverse events and changes in disease activity of oral ABBV-453, given alone or with subcutaneous and/…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: TriPRIL CAR T Cells in Multiple Myeloma [Phase 1]
This document summarizes an ongoing Phase 1 clinical trial evaluating TriPRIL CAR T Cells in patients with multiple myeloma, including relap…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) [Phase 2, Phase 3]
A Phase 2/3 clinical trial update announcing a study comparing Linvo-VR against the DVRd regimen in transplant-eligible adults with newly di…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial (NCT05530421) evaluating selinexor, venetoclax, and dexamethasone (XVenD) in t(11;14)-positive relapsed/refractory …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating maintenance therapy with isatuximab and lenalidomide after autologous stem cell transplant in MRD-positive…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating subcutaneous isatuximab with weekly carfilzomib and dexamethasone in adults with relapsed and/or refr…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring [NA]
Carevive Systems is conducting a real-world study evaluating remote symptom monitoring for patients with breast cancer, lung cancer, gastroi…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
A clinical trial update describing a real-world study on treatment experiences for breast, lung, ovarian cancer, multiple myeloma, and acute…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial update evaluating anti-BCMA CAR-T cells for relapsed or refractory multiple myeloma; the study is currently active bu…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
A multicenter prospective observational cohort study in patients with multiple myeloma to evaluate how cancer-directed treatment and medicat…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Elranatamab in Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial of Elranatamab for relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care [NA]
This clinical trial update describes a University of Miami-sponsored study evaluating how Leukemia & Lymphoma Society services affect patien…
-
FDA label_change · 2026-02-19FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) from U.S. Pharmaceuticals, resulting in an update to its labeling/in…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma [Phase 2]
Phase 2 trial evaluating pre-transplant purging and post-transplant MRD-guided maintenance therapy with elranatamab in high-risk multiple my…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
A study by Memorial Sloan Kettering Cancer Center aims to identify barriers to cellular therapies for people with plasma cell disorders, inc…
-
CLINICAL_TRIALS other · 2026-02-19Clinical Trial Update: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. [Phase 1, Phase 2]
Phase I/II study of SENL103 for relapsed or refractory multiple myeloma is listed as not yet recruiting, representing an early-stage, non-en…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating induction therapy with lenalidomide, bortezomib, and dexamethasone plus isatuximab given either intravenously or …